2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer

Gavin Stuart(Medtronic (Ireland)), Henry C Kitchener(LifeArc), Monica Bacon(Georgia Canines for Independence), Andreas duBois(Arbeitsgemeinschaft Gynäkologische Onkologie Studiengruppe), Michael Friedländer(ANZCHOG), Jonathan A. Ledermann(LifeArc), Christian Marth(AGO Austria), Tate Thigpen(Gynecologic Oncology Group), Edward L. Trimble
International Journal of Gynecological Cancer
April 1, 2011
10.1097/igc.0b013e31821b2568
Cited by 423

Abstract

Related Papers

Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Deborah K. Armstrong, Brian N. Bundy, Lari Wenzel et al.|New England Journal of Medicine|2006|2.6k
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Ignace Vergote, Claes G. Tropé, Frédéric Amant et al.|New England Journal of Medicine|2010|2.5k
Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial
Noriyuki Katsumata, Makoto Yasuda, Fumiaki Takahashi et al.|The Lancet|2009|733
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)
Andreas du Bois, Michael Quinn, Tate Thigpen et al.|Annals of Oncology|2005|465
Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study.
Robert A. Burger, Mark F. Brady, Michael A. Bookman et al.|Journal of Clinical Oncology|2010|186